Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
نویسندگان
چکیده
منابع مشابه
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
Type 2 diabetes mellitus (T2DM) is a growing worldwide epidemic. Patients face lifelong therapy to control hyperglycemia and prevent the associated complications. There are many medications, with varying mechanisms, available for the treatment of T2DM, but almost all target the declining insulin sensitivity and secretion that are associated with disease progression. Medications with such insuli...
متن کاملEuglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.
More than 10 million Canadians are currently living with diabetes.1 Of those, 90% have type 2 diabetes mellitus (T2DM).1 Recently launched oral medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors were approved by the US Food and Drug Administration (FDA) in 2013 for treating T2DM.2 Approval by Health Canada was granted in 2014.3 Treatment with SGLT2 inhibitors (canagliflozin,...
متن کاملSodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs. PURPOSE To assess the efficacy and safety of SGLT2 inhibitors in adults with type 2 diabetes. DATA SOURCES MEDLINE, EMBASE, and the Cochrane Library from inception through April 2013 without language restrictions; regulatory authorities' reports; and gray literature. STUDY SELECTION Randomi...
متن کاملType 2 Diabetes, Iron, Exercise Therapy, Glycemic Control
Background and aims: Previous research has shown that one of the factors associated with type II diabetes and insulin resistance is impaired iron metabolism; also, one of the elemental keys in type II diabetes is regular exercise. The aim of this study was to evaluate the effect of moderate intensity body pump training on iron-related indices in women with type II diabetes. Methods: In the pr...
متن کاملRandomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
AIMS/INTRODUCTION In the present dose-response study, we evaluated the efficacy and safety of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose cotransporter 2, in Japanese patients with type 2 diabetes mellitus. MATERIALS AND METHODS A total of 361 patients from 39 Japanese centers were randomized to receive either once-daily oral ipragliflozin (12.5, 25, 5...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutics and Clinical Risk Management
سال: 2018
ISSN: 1178-203X
DOI: 10.2147/tcrm.s137068